Enhanced Anti-CD25 Antibody-Maytansine Conjugates for Cancer Treatment
Legal Citation
Summary of the Inventive Concept
Improved anti-CD25 antibody-maytansine conjugates and methods for treating cancer, addressing limitations of existing conjugates through enhanced potency, solubility, and efficacy.
Background and Problem Solved
The original patent disclosed anti-CD25 antibody-maytansine conjugates with limitations in potency, solubility, and efficacy. The new inventive concept addresses these limitations by introducing modifications to the maytansinoid, conjugation methods, and formulations to provide improved cancer treatment options.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for treating cancer with a conjugate of formula (I) and a pharmaceutical carrier, administered in a dose-escalating regimen to minimize side effects. Additionally, the concept includes methods for improving efficacy by modifying the maytansinoid to have higher potency and administering the conjugate with an immunomodulatory agent. The conjugate can be further enhanced with a polyethylene glycol (PEG) moiety to improve solubility and stability. A kit for preparing the conjugate and a novel purification process using affinity chromatography are also disclosed.
Novelty and Inventive Step
The new claims introduce novel modifications to the maytansinoid, conjugation methods, and formulations, which are not obvious from the original patent. The inventive step lies in the combination of these modifications to provide improved potency, solubility, and efficacy in cancer treatment.
Alternative Embodiments and Variations
Alternative embodiments include varying the linker design, using different immunomodulatory agents, and modifying the pharmaceutical carrier. Variations of the conjugate formula, such as using different maytansinoids or antibodies, could also be explored.
Potential Commercial Applications and Market
The enhanced anti-CD25 antibody-maytansine conjugates have significant commercial potential in the cancer treatment market, particularly in the areas of lymphoma and leukemia. The inventive concept could be licensed to pharmaceutical companies or developed in-house for commercialization.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/6807 |
| C | C07 | C07K16/2866 |
| A | A61 | A61K47/65 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Protein-small molecule therapeutic conjugates, specifically antibody-drug conjugates targeting CD25 for cancer treatment, requiring expertise in protein chemistry, conjugation techniques, and pharmaceutical formulation
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with a PhD in biochemistry or pharmaceutical sciences, experienced in antibody engineering, drug conjugation methods, and cancer therapeutic design, familiar with protein modification techniques and drug delivery strategies
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's modifications represent predictable variations of the source patent's core antibody-maytansine conjugate technology. The disclosed improvements in conjugation efficiency, solubility enhancement, and dosing strategies are logical extensions of existing knowledge in antibody-drug conjugate development. The technical modifications represent incremental advancements that would be apparent to a skilled practitioner seeking to optimize therapeutic performance.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,637 |
|---|---|
| Title | Anti-CD25 antibody-maytansine conjugates and methods of use thereof |
| Assignee(s) | R.P. Scherer Technologies, LLC |